human-lungs-and-tablet-10086136In a clinical trial that was stopped early, researchers found that patients with ventilator-associated bacterial pneumonia who took 7 days of Doribax had a higher 28-day all-cause mortality of 23% compared to 16.7 % in those who took Primaxin (imipenem/cilastatin ). The cure rates were also lower in the Doribax arm which led the FDA to approve changes to the drug label. The package insert now includes a warning on using Doribax to treat ventilator associated bacterial pneumonia. Doribax is still FDA-approved to treat complicated intra-abdominal infections and complicated urinary tract infections.

What medications would you recommend to treat ventilator associated bacterial pneumonia?

For additional information, please visit FDA and the updated Doribax Drug Label

Image courtesy of [dream designs]/FreeDigitalPhotos.net

Advertisements